| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,390 | -2,010 | -3,450 | -3,220 | -4,560 |
| Net Income Growth | -68.66% | +41.74% | -7.14% | +29.39% | +23.87% |
Virpax Pharmaceuticals Inc (VRPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals Inc. is based in WEST CHESTER, PA.
Fiscal Year End Date: 12/31